REPROCELL

Regenerative Medicine · Drug Discovery
Lately:2 news stories in 90 daysFollow changes →

Facts

as of Nov 18, 2026

REPROCELL develops and supplies human iPSC-derived cells, primary human biospecimens and related cell-based tools for research and drug discovery. The company offers preclinical assay services using fresh human tissues, molecular and assay development services, and contract research to support drug discovery and regenerative medicine programs. Founded in 2003 with operations and partnerships across the United States, United Kingdom, India and Japan, REPROCELL serves pharmaceutical, biotech and academic customers worldwide.

Founded
1970
Website
reprocell.com
Sources: company registers, GLEIF, Wikidata, the company's site, Alion job postingsReport a mistake

What the registers and the postings say about this employer.

Sanctions lists
OFAC SDN, EU consolidated
No match
Phishing reports
OpenPhish, Phishing.Database
None
Layoff notices
US WARN notices on file
None
Full employer checkScam signs in adverts, mail records, visa registers, domain history
Sources: company registers, the Alion truth index, OFAC and EU sanctions lists, US WARN notices

Footprint

Hiring in 2 cities in 1 country.

2Cities
1Countries
Loading the map
SiteTypeOpen rolesHires most forEngineering
Yokohama JapanRegional office0
Usa JapanRegional office0
Source: office addresses in postings and company registers

Newsroom

top 2%Web presenceof 133.2M domains by links, Common Crawl
Sep 252026
News · investing.com
Aug 202026
News · uk.investing.com
Jun 242026
News · YahooFinance
REPROCELL Inc. today announced the submission of an application for manufacturing and marketing approval in Japan for the regenerative medicine product Stemchymal, for which the…
Jan 282026
Press release · PRNewswire
/PRNewswire/ -- REPROCELL today announced the commercial launch of StemEdit, its clinical gene editing services and new gene-edited iPSC product lines...
Sources: the outlets named on each headline, each story once